Search | Page 13 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

    ... and response. Treatment consisted on a combination of azacitidine and vorinostat. Thirty patients (16 with MDS, 14 with AML) were ... the study and treated 79 additional patients: 27 with azacitidine (AZA) and 52 with azacitidine and vorinostat (AZA+V). Median ...

    Research Article last updated 11/28/2016 - 11:15am.

  2. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

    ... , alone or in combination with ESAs; oral azacitidine ; and new molecules such as the activin receptor type II ligand ...

    Research Article last updated 12/09/2016 - 2:50pm.

  3. MDS/AML patients benefit from novel study

    ... 109 patients with AML and MDS undergoing treatment with azacitidine (AZA) and vorinostat. Research results were presented Dec. 3 at ...

    Article last updated 12/08/2016 - 2:34pm.

  4. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes

    ... that alter the natural history of the disease. Azacitidine is the only drug reported to improve overall survival in higher ...

    Research Article last updated 09/19/2016 - 11:11am.

  5. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    ... Azacitidine treatment is effective in higher risk MDS (HR-MDS), with less ...

    Research Article last updated 09/13/2016 - 2:47pm.

  6. Top expert calls future MDS/AML care “promising”

    ... agents, such as SGI-110 (guadecitabine) or CC-486 (oral azacitidine ). What are the ongoing clinical trials in this space? ...

    Article last updated 11/02/2016 - 11:28am.

  7. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... CC-486 is an oral formulation of the epigenetic modifier azacitidine . In an expanded phase 1 trial, CC-486 demonstrated clinical and ...

    Research Article last updated 06/23/2016 - 10:17am.

  8. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... syndromes with excess blasts after failure of azacitidine or decitabine treatment. METHODS: We did this ...

    Research Article last updated 06/07/2016 - 11:10am.

  9. Recent developments in myelodysplastic syndromes

    ... in the United States (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and ...

    Research Article last updated 04/29/2016 - 11:34am.

  10. Myelodysplastic syndromes: Contemporary review and how we treat

    ... limited; they include the hypomethylating agents (HMA) azacitidine and decitabine and lenalidomide for MDS with ...

    Research Article last updated 04/29/2016 - 1:05pm.